JAZZ
Undervalued by 126.1% based on the discounted cash flow analysis.
Market cap | $6.66 Billion |
---|---|
Enterprise Value | $10.25 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $9.06 |
Beta | 0.38 |
Outstanding Shares | 60,979,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 13.67 |
---|---|
PEG | 2.56 |
Price to Sales | 1.67 |
Price to Book Ratio | 1.62 |
Enterprise Value to Revenue | 2.52 |
Enterprise Value to EBIT | 17.25 |
Enterprise Value to Net Income | 21 |
Total Debt to Enterprise | 0.53 |
Debt to Equity | 1.31 |
No data
No data
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...